UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25
UBS analyst Alice Nettleton initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $25.
Stocks · News reference
William Blair Initiates Coverage On Kardigan with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Kardigan (NASDAQ:KARD) with a Outperform rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Kardigan, Inc. (KARD)
Filed: 2026-09-30 AccNo: 0001193125-26-408348 Size: 198 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.